Short term effects of tiotropium on COPD patients treated with long acting bronchodilators

Tanaffos

Volumn 11, Issue 1, 2012, Pages 26-31

  Nicolini, Antonello ^a  

^a Hospital of Sestri Levante   (Italy)

Author keywords

Chronic obstructive pulmonary disease; Pulmonary function; Six minute walk test; Tiotropium

Indexed keywords

PLACEBO; SALMETEROL; TIOTROPIUM BROMIDE;

AGED; ARTICLE; BEDTIME DOSAGE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EXERCISE; EXERCISE TOLERANCE; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SPIROMETRY; TREATMENT RESPONSE;

EID: 84858772644     PISSN: 17350344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Hodder R, Kesten S, Menjoge S, Viel K. Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids. Int J Chron Obstruct Pulmon Dis 2007; 2 (2): 157-67.
2. Anzueto A. Clinical course of chronic obstructive pulmonary disease: review of therapeutic interventions. Am J Med 2006; 119 (10 Suppl 1): 46-53.
3. Barnes PJ. New development in anticholinergic drugs. Eur Respir Rev 1996; 6: 290-4.
4. Celli BR. The importance of spirometry in COPD and asthma: effect on approach to management. Chest 2000; 117 (2 Suppl): 15S-9S.
5. O'Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164 (5): 770-7.
6. Disse B, Witek TJ JR. Anticholinergics: tiotropium. In: Hansel TT, Barnes PJ, editors. Progress in respiratory research. Vol 31. New drugs for asthma, allergy and COPD. London, Karger, 2000.
7. Vincken W, van Noord JA, Greefhorst AP, Bantje TA, Kesten S, Korducki L, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002; 19 (2): 209-16.
8. Celli B, ZuWallack R, Wang S, Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003; 124 (5): 1743-8.
9. Maltais F, Hamilton A, Marciniuk D, Hernandez P, Sciurba FC, Richter K, et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest 2005; 128 (3): 1168-78.
10. van Noord JA, Bantje TA, Eland ME, Korducki L, Cornelissen PJ. A randomised controlled comparison of tiotropium nd ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax 2000; 55 (4): 289-94.
11. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58 (5): 399-404.
12. Cazzola M, Centanni S, Santus P, Verga M, Mondoni M, di Marco F, et al. The functional impact of adding salmeterol and tiotropium in patients with stable COPD. Respir Med 2004; 98 (12): 1214-21.
13. van Noord JA, Aumann JL, Janssens E, Smeets JJ, Verhaert J, Disse B, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005; 26 (2): 214-22.
14. Cazzola M, Di Marco F, Santus P, Boveri B, Verga M, Matera MG, et al. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm Pharmacol Ther 2004; 17 (1): 35-9.
15. Brusasco V, Crapo R, Viegi G. ATS/ERS Task Forces standardisation of lung function testing. Eur Resp J 2005; 26: 319-38.
16. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS; GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163 (5): 1256-76.
17. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166 (1): 111-7.
18. Cerveri I, Ansaldo E. Effects of tiotropium on pulmonary function Italian Review of Respiratory Disease 2008: suppl 23;5-9.
19. Soriano JB, Mannino DM. Reversing concepts on COPD irreversibility. Eur Respir J 2008; 31 (4): 695-6.
20. Rossi A. Tiotropium: a drug for COPD Italian Review of Respiratory Dis 2008; suppl 23: 28-30.
21. Welte T, Miravitlles M, Hernandez P, Eriksson G, Peterson S, Polanowski T, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180 (8): 741-50.
22. van Noord JA, Aumann JL, Janssens E, Verhaert J, Smeets JJ, Mueller A, et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006; 129 (3): 509-17.
23. Cazzola M, Andò F, Santus P, Ruggeri P, Di Marco F, Sanduzzi A, et al. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD. Pulm Pharmacol Ther 2007; 20 (5): 556-61.
24. Perng DW, Wu CC, Su KC, Lee YC, Perng RP, Tao CW. Additive benefits of tiotropium in COPD patients treated with long-acting beta agonists and corticosteroids. Respirology 2006; 11 (5): 598-602.